Company Profile

NGM Biopharmaceuticals, Inc. is a United States-based biopharmaceutical company. The Company discovers and develops medicines for diseases like cancer, liver and metabolic diseases, and retinal diseases. Its Bio's pipeline candidates includes: Aldafermin, FGF19 Analog, NGM120, NGM707 + pembrolizumab, ILT2/ILT4 Dual Antagonist + PD-1 Antagonist Antibody and NGM831 + NGM438 + pembrolizumab.

Employees

138

Sector

Biotechnology & Medical Research

More about the company

03-26	NGM Biopharmaceuticals, Inc. announced that it has received $142.039949 million in funding from The Column Group, LLC and other investors	CI
25-02-24	NGM Bio Announces First Participant Dosed in EMERALD Phase 2 Clinical Study of NGM120 for the Treatment of Hyperemesis Gravidarum (HG) in Pregnant Patients	CI
25-02-04	NGM Biopharmaceuticals, Inc. Announces Management Changes	CI
24-12-19	NGM Biopharmaceuticals, Inc. and KdT Ventures Enter into Worldwide License Agreement for NGM313, Phase 2-Ready FGFR1c/ß-Klotho Agonist Drug Candidate	CI
24-07-16	NGM Biopharmaceuticals, Inc. announced that it has received $122.000001 million in funding from The Column Group, LLC and other investors	CI
24-07-02	NGM Biopharmaceuticals, Inc. announces a financing transaction	CI
24-04-04	NGM Biopharmaceuticals, Inc.(NasdaqGM:NGM) dropped from NASDAQ Composite Index	CI
24-04-04	The Column Group, LLC completed the acquisition of 74% stake in NGM Biopharmaceuticals, Inc. from other group of shareholders.	CI
24-04-04	NGM Biopharmaceuticals, Inc.(NasdaqGS:NGM) dropped from S&P Global BMI Index	CI
24-04-04	NGM Biopharmaceuticals, Inc.(NasdaqGS:NGM) dropped from S&P TMI Index	CI
24-03-12	Raymond James Downgrades NGM Biopharmaceuticals to Market Perform From Outperform	MT
24-03-11	NGM Biopharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
24-03-11	NGM Biopharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

24-03-12	Raymond James Downgrades NGM Biopharmaceuticals to Market Perform From Outperform	MT
24-02-28	B. Riley Lowers NGM Biopharmaceuticals' PT to $1.55 From $3.50 on Heels of Announced Sale Agreement With Affiliates of The Column Group, Keeps Buy Rating	MT
24-02-28	TD Cowen Downgrades NGM Biopharmaceuticals to Market Perform From Outperform, Adjusts Price Target to $1.55 From $4	MT
23-11-22	B. Riley Lowers NGM Biopharmaceuticals' Price Target to $3.50 From $7, Maintains Buy Rating	MT
23-05-03	Citigroup Starts NGM Biopharmaceuticals at Buy With $6 Price Target	MT

24-04-05	NGM Bio Announces Closing of Tender Offer	GL
24-03-19	NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting	GL
24-03-13	NGM BIOPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NGM Biopharmaceuticals, Inc. - NGM	BU
24-03-11	NGM Biopharmaceuticals: Q4 Earnings Snapshot	AQ
24-03-11	NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results	GL

3 years	0.6	2.2
5 years	0.6	21.63
10 years	0.6	32.12

Manager	Title	Age	Since
Diana Bockus CEO	Chief Executive Officer	-	2025-03-31
Dhiraj Abhyankar CTO	Chief Tech/Sci/R&D Officer	-	-
Daniel Kaplan CTO	Chief Tech/Sci/R&D Officer	-	2023-03-31

NGM Biopharmaceuticals, Inc. Stock

Stocks

NGM

US62921N1054

Biotechnology & Medical Research

Latest news: NGM Biopharmaceuticals, Inc.

Analysts' recommendations: NGM Biopharmaceuticals, Inc.

Press Releases: NGM Biopharmaceuticals, Inc.

News in other languages: NGM Biopharmaceuticals, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: NGM Biopharmaceuticals, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Company Profile

Director	Title	Age	Since
William Rieflin CHM	Chairman	66	2018-08-31
Roger Perlmutter BRD	Director/Board Member	73	2021-06-07
Diana Bockus BRD	Director/Board Member	-	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
4/5/24	Shelly Guyer	Issuer sale	Director	188,251	0.2256%
4/5/24	David Woodhouse	Tender	Chief Executive Officer	3,548,493	4.2516%
4/5/24	The Column Group LLC	Issuer sale	Company	21,744,413	26.0529%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NGM BIOPHARMACEUTICALS, INC.	-1.28%	-.--%	-	-	129M
WUXI APPTEC CO., LTD.	-0.62%	+0.50%	+33.92%	+60.07%	64.38B
ARGENX SE	+1.09%	+3.96%	+15.77%	+85.92%	56.16B
LONZA GROUP AG	+0.31%	+2.15%	+15.58%	+107.19%	54.16B
IQVIA HOLDINGS INC.	-2.65%	-3.77%	+24.18%	+51.74%	45.33B
BEONE MEDICINES AG	+0.28%	-1.15%	+21.12%	+100.05%	42.25B
REVOLUTION MEDICINES, INC.	-0.76%	+1.40%	+222.07%	+933.24%	40.78B
GENMAB A/S	+2.88%	+47.58%	+112.12%	+95.98%	33.8B
CELLTRION, INC.	+1.22%	-1.39%	+13.92%	+46.95%	32.25B
WUXI BIOLOGICS (CAYMAN) INC.	-1.29%	-1.72%	+21.00%	-6.85%	23.57B
Average	-0.09%	+4.72%	+53.30%	+163.81%	43.63B
Weighted average by Cap.	+0.01%	+3.64%	+50.15%	+162.29%